Ligand, Pfizer deal

LGND said it will elect to receive its next two milestones from Pfizer in LGND stock already held by the pharma company. The payments were agreed as part of the settlement of a lawsuit between the companies (see BioCentury April 22), which are developing Droloxifene, a Pfizer compound in Phase III trials for breast cancer and Phase II trials for osteoporosis. ...